Analysis of highly potent amidine containing inhibitors of serine proteases and their N-hydroxylated prodrugs (amidoximes)

Journal of Enzyme Inhibition and Medicinal Chemistry

Volumn 26, Issue 1, 2011, Pages 115-122

  Kotthaus, Joscha ^a   Steinmetzer, Torsten ^b   Van De Locht, Andreas ^c   Clement, Bernd ^a  

^a UNIVERSITY OF KIEL   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c Medicines Company   (Germany)

Author keywords

amidine; amidoxime; HPLC; prodrug; Serine protease inhibitor

Indexed keywords

AMIDINE; AMIDOXIME DERIVATIVE; BENZAMIDINE; CJ 1200; CJ 1331; CJ 1332; CJ 1707; CJ 1764; CJ 1802; CJ 1803; CJ 1817; CJ 2026; CJ 463; CJ 929; CJ 930; ETHYLMELAGATRAN; MELAGATRAN; MESUPRON; N HYDROXY BENZAMIDINE; N HYDROXYMELAGATRAN; PRODRUG; RO 44 3888; RO 48 3656; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; WX 671; XIMELAGTRAN;

ARTICLE; DRUG ANALYSIS; DRUG BIOAVAILABILITY; DRUG STRUCTURE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIPOPHILICITY; MASS SPECTROMETRY; PHYSICAL CHEMISTRY; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; AMIDINES; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; HYDROXYLATION; INTESTINAL ABSORPTION; MASS SPECTROMETRY; PRODRUGS; SENSITIVITY AND SPECIFICITY; SERINE PROTEASES; SERINE PROTEINASE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79851480026     PISSN: 14756366     EISSN: 14756374     Source Type: Journal    
DOI: 10.3109/14756361003733647     Document Type: Article

References (25)

1. Abbenante G, Fairlie DP. Protease inhibitors in the clinic. Med Chem 2005;1:71-104.
2. Schweinitz A, Steinmetzer T, Banke IJ, Arlt MJ, Stürzebecher A, Schuster O, Geissler A, Giersiefen H, Zeslawska E, Jacob U, Kruger A, Stürzebecher J. Design of novel and selective inhibitors of urokinase-type plasminogen activator with improved pharmacokinetic properties for use as antimetastatic agents. J Biol Chem 2004;279:33613-33622. (Pubitemid 39063010)
3. Förbs D, Tiel S, Stella MC, Stürzebecher A, Schweinitz A, Steinmetzer T, Stürzebecher J, Uhland K. In vitro inhibition of matriptase prevents invasive growth of cell lines of prostate and colon carcinoma. Int J Oncol 2005;27:1061-1070.
4. Steinmetzer T, Schweinitz A, Stürzebecher A, Dönnecke D, Uhland K, Schuster O, Steinmetzer P, Muller F, Friedrich R, Tan ME, Bode W, Stürzebecher J. Secondary amides of sulfonylated 3-amidinophenylalanine. New potent and selective inhibitors of matriptase. J Med Chem 2006;49:4116-4126. (Pubitemid 44036657)
5. Uhland K. Matriptase and its putative role in cancer. Cell Mol Life Sci 2006;63:2968-78. (Pubitemid 46072302)
6. Eriksson BI, Quinlan DJ. Oral anticoagulants in development: focus on thromboprophylaxis in patients undergoing orthopaedic surgery. Drugs 2006;66:1411-1429.
7. Ansell J. Factor Xa or thrombin: is factor Xa a better target? J Tromb Haemost 2007;5:60-64. (Pubitemid 46958817)
8. Haas S. New anticoagulants-towards the development of an "ideal" anticoagulant. Vasa 2009;38:13-29.
9. Werbovetz K. Diamidines as antitrypanosomal, antileishmanial and antimalarial agents. Curr Opin Investig Drugs 2006;7:147-157. (Pubitemid 43230911)
10. Peterlin-Masic L, Cesar J, Zega A. Metabolism-directed optimisation of antithrombotics: the prodrug principle. Curr Pharm Des 2006;12:73-91.
11. Clement B. Reduction of N-hydroxylated compounds: amidoximes (N-hydroxyamidines) as pro-drugs of amidines. Drug Metab Rev 2002; 34:565-679.
12. Havemeyer A, Bittner F, Wollers S, Mendel R, Kunze T, Clement B. Identifcation of the missing component in the mitochondrial benz-amidoxime prodrug-converting system as a novel molybdenum enzyme. J Biol Chem 2006;281:34796-34802. (Pubitemid 46036518)
13. Grünewald S, Wahl B, Bittner F, Hungeling H, Kanzow S, Kotthaus J, Schwering U, Mendel RR, Clement B. Te Fourth Molybdenum Containing Enzyme mARC: Cloning and Involvement in the Activation of N-Hydroxylated Prodrugs. J Med Chem 2008;51:8173-8177.
14. Pelkonen O, Turpeinen M, Hakkola J, Honkakoski P, Hukkanen J, Raunio H. Inhibition and induction of human cytochrome P450 enzymes: current status. Arch Toxicol 2008;82:667-715.
15. Weller T, Alig L, Beresini M, Blackburn B, Bunting S, Hadvary P, Muller M, Knopp D, Levet-Traft B, Lipari M, Modi N, Muller M, Refno C, Schmitt M, Schonholzer P, Weiss S, Steiner B. Orally active fbrinogen receptor antagonists. 2. Amidoximes as prodrugs of amidines. J Med Chem 1996;39:3139-3147. (Pubitemid 26260319)
16. Stürzebecher J, Vieweg H, Steinmetzer T, Schweinitz A, Stubbs MT, Renatus M, Wikström P. 3-Amidinophenylalanine-based inhibitors of urokinase. Bioorg Med Chem Lett 1999;9:3147-3152. (Pubitemid 29515398)
17. Stürzebecher A, Dönnecke D, Schweinitz A, Schuster O, Steinmetzer P, Stürzebecher U, Kotthaus J, Clement B, Stürzebecher J, Steinmetzer T. Highly potent and selective substrate analogue factor Xa inhibitors containing D-homophenylalanine analogues as P3 residue: part 2. ChemMedChem 2007;2:1043-1053.
18. Schweinitz A, Dönnecke D, Ludwig A, Steinmetzer P, Schulze A, Kotthaus J, Wein S, Clement B, Steinmetzer T. Incorporation of neutral C-terminal residues in 3-amidinophenylalanine-derived matriptase inhibitors. Bioorg Med Chem Lett 2009;19:1960-1965.
19. Krueger P. Über Abkömmlinge des Benzenylamidoxims. Ber Dtsch Chem Ges 1885;18:1055-1060.
20. Gummow B, du Preez JL, Swan GE. Paired-ion extraction and high-performance liquid chromatographic determination of diminazene in cattle plasma: a modifed method. Onderstepoort J Vet Res 1995;62:1-4.
21. Clement B, Lopian K. Characterization of in vitro biotransformation of new, orally active, direct thrombin inhibitor ximelagatran, an amidoxime and ester prodrug. Drug Metab Dispos 2003;31:645-651. (Pubitemid 36444174)
22. Clement B, Mau S, Deters S, Havemeyer A. Hepatic, extrahepatic, microsomal, and mitochondrial activation of the N-hydroxylated prodrugs benzamidoxime, guanoxabenz, and Ro 48-3656 ([[1-[(2s)-2-[[4-[(hydroxyamino) iminomethyl]benzoyl]amino]-1-oxopropyl]-4-piperidinyl]oxy]-acetic acid). Drug Metab Dispos 2005;33:1740-1747.
23. Clement B, Bürenheide A, Rieckert W, Schwarz J. Diacetyldiamidoximeester of pentamidine, a prodrug for treatment of protozoal diseases: synthesis, in vitro and in vivo biotransformation. ChemMedChem 2006;1:1260-7. (Pubitemid 44786932)
24. Albert A, Goldacre R, Phillips J. Te strength of heterocyclic bases. J Chem Soc 1948;2240-2249.
25. Gustafsson D, Bylund R, Antonsson T, Nilsson I, Nystrom JE, Eriksson U, Bredberg U, Teger-Nilsson AC A new oral anticoagulant: the 50-year challenge. Nat Rev Drug Discov 2004;3:649-659. (Pubitemid 39173506)